Compare WEA & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEA | BDSX |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | WEA | BDSX |
|---|---|---|
| Price | $10.85 | $14.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 28.7K | ★ 71.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $10.16 | $0.25 |
| 52 Week High | $11.44 | $20.21 |
| Indicator | WEA | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 48.15 |
| Support Level | $10.65 | $6.33 |
| Resistance Level | $10.85 | $20.21 |
| Average True Range (ATR) | 0.14 | 1.22 |
| MACD | 0.05 | -0.24 |
| Stochastic Oscillator | 83.61 | 35.06 |
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.